Showing 6401-6410 of 9765 results for "".
- Study: Most Global Melanoma Cases Attributable to UV Exposurehttps://practicaldermatology.com/news/study-most-global-melanoma-cases-attributable-to-uv-exposure/2474874/A new global analysis of cutaneous melanoma (CM) shows ultraviolet radiation (UVR) as the primary driver behind the majority of CM cases worldwide in 2022. Researchers used updated incidence estimates from GLOBOCAN 2022 (exclud
- HADLIMA Cleared for Substitution with Humira in All Forms: FDAhttps://practicaldermatology.com/news/hadlima-cleared-for-substitution-with-humira-in-all-forms-fda/2474836/The US Food and Drug Administration (FDA) has granted full interchangeability status to adalimumab-bwwd (HADLIMA™), a biosimilar of Humira® (adalimumab), across all forms and concentrations, according to a press release from Organon.
- Assessment Tool Combination Reveals Higher AD Risk and Atopic March Progressionhttps://practicaldermatology.com/news/assessment-tool-combination-reveals-higher-ad-risk-and-atopic-march-progression/2474810/Children with Staphylococcus aureus (SA) detected by metagenomic sequencing, as well as culture-based methods, had worse atopic dermatitis (AD) outcomes, new study results suggest. Des
- Analysis Forecasts 140% Rise in Basal Cell Carcinoma by 2050https://practicaldermatology.com/news/analysis-forecasts-140-rise-in-basal-cell-carcinoma-by-2050/2474797/The global burden of skin cancer among adults aged 65 and older has increased steadily over the past three decades and is expected to continue rising through 2050, according to a new analysis of Global Burden of Disease (GBD) Study data.
- ElderDerm Co-Director Suggests Alternatives for 'Senile' in Diagnoseshttps://practicaldermatology.com/news/ElderDerm-Co-Director-Suggests-Alternatives-Senile-Diagnoses/2474689/The word senile can be avoided in discussing dermatologic diseases, Jaya Manjunath, MSIV, asserted at the ElderDerm 2025 Conference in Washington, DC. Manjunath, a medical student and co-director of the conference along with Practical Dermatology editorial board member Adam Friedm
- Arcutis Announces Expert Statements on Genital Psoriasishttps://practicaldermatology.com/news/arcutis-announces-expert-statements-on-genital-psoriasis/2474665/Arcutis Biotherapeutics, Inc. has announced new consensus statements aimed at improving the diagnosis and management of genital psoriasis, according to a company press release. The 14 statements, developed by a multidisciplinary group of dermatology and immunology experts with the Genital
- Study: Nonprescription Balm Performs on Par with Topical Antibiotichttps://practicaldermatology.com/news/study-nonprescription-balm-performs-on-par-with-topical-antibiotic/2474439/A new randomized controlled trial found that a nonprescription repairing balm containing panthenol, madecassoside, and metal salts (CB5) performs equivalently to a topical antibiotic (PSO) for wound healing after cryotherapy of actinic keratoses (AKs).
- Market for Atopic Dermatitis Treatments to Surge Past $22 Billionhttps://practicaldermatology.com/news/market-for-atopic-dermatitis-treatments-to-surge-past-22-billion/2474524/The global atopic dermatitis (AD) market is projected to more than double over the next decade, reaching $22.37 billion by 2034, new research from Polaris Market Research indicates. Driven by an annual growth rate of 8.5%, the
- Simvastatin Shows Promise as Adjunct Treatment for Vitiligo in Meta-Analysishttps://practicaldermatology.com/news/simvastatin-shows-promise-as-adjunct-treatment-for-vitiligo-in-meta-analysis/2474442/A new meta-analysis highlights the therapeutic potential of simvastatin for vitiligo, showing significant benefits in repigmentation and disease severity reduction. Vitiligo, an autoimmune disorder marked by melanocyte destruc
- ARRECTOR: Roflumilast Foam 0.3% Shows Strong Efficacy for Scalp and Body Psoriasishttps://practicaldermatology.com/news/arrector-roflumilast-foam-shows-strong-efficacy-for-scalp-and-body-psoriasis/2474520/A once-daily roflumilast foam formulation significantly improved scalp and body psoriasis in a pivotal phase 3 trial, according to a press release from Arcutis Biotherapeutics, Inc. Researchers for the randomized, double-blin